Adherex Technologies is reacquiring Cadherin Biomedical in a deal worth some $1.5 million.

Adhereix, a biopharmaceutical company, said Friday that the decision has been approved by the boards of both firms. The company said the deal also settles legal claims filed by both firms in a dispute over goods and services as well as license agreements.

Cadherin stockholders will receive 3.2 million shares of Adherex (TSX: AHX) stock.